Compare Heron Therapeutics Inc (HRTX) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs BlackRock TCP Capital Corp — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while BlackRock TCP Capital Corp trades at $3.25 (market cap $270.17M). The key difference: BlackRock TCP Capital Corp is far larger — about 3× Heron Therapeutics Inc's market cap, and BlackRock TCP Capital Corp pays a 26.09% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | TCPC | |
|---|---|---|
Market Cap | $91.46M | $270.17M |
Sector | Health | Financials |
52-Week High | $1.96 | $7.64 |
52-Week Low | $0.39 | $3.14 |
Enterprise Value | $189.36M | — |
Dividend Yield | — | 26.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
TCPC trades at $3.21, down 3.02% today, with a bearish technical signal and negative revenue trends. The company reported a net loss of $88.93M in 2025, though it maintains a 112% net income margin due to accounting adjustments. Recent news includes a Zacks upgrade to Buy and an upcoming Q2 2026 earnings report on August 6, 2026.
Outlook remains cautious with mixed analyst sentiment (30.77% Buy) and ongoing legal scrutiny. The stock's low P/B of 0.49 suggests potential value, but persistent losses and negative cash flow pose significant risks. Dividend sustainability is a key concern amid financial pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
